A Study of BGB-24714 as Monotherapy and With Combination Therapies in Participants With Solid Tumors
Terminated · Phase 1 · NCT05381909
Conditions: Solid Tumor, Adult
At a glance
- Research payments reported, 2025
- $1.1M
- U.S. investigators named
- 15
- Sites paid
- 14
- Planned or actual enrollment
- 157
About the trial
- Sponsor
- BeiGene
- Tested
- BGB-24714 (drug), Paclitaxel (drug), Carboplatin (drug), Docetaxel (drug)
- Dates
- Started 2022-07-06; completion 2025-07-25
- Results posted
- Not yet
This study aims to understand how safe and well-tolerated a drug called BGB-24714 is when used alone, or in combination with chemotherapy or radiation therapy, for people with advanced or spreading solid tumors. The main objective is to identify the highest tolerable dose or the highest administered dose of BGB-24714. Additionally, the study aims to identify the most suitable doses for further investigation in larger groups of participants.
From ClinicalTrials.gov, last updated 2026-02-20. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Beone Medicines Ltd. reported $1.1M in research payments for this study in 2025 (181 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Jiaxin Niu, MD Hematology & Oncology · Gilbert, AZ
- Maen A. Hussein, M.D. Medical Oncology · Lady Lake, FL
- Bradley J. Monk, MD Gynecologic Oncology · West Palm Beach, FL
- Judy S. Wang, MD Medical Oncology · Sarasota, FL
- Andreas Varkaris, MD Hematology & Oncology · Boston, MA
- Ira S. Winer, MD Gynecologic Oncology · Royal Oak, MI
- Andrew Z. Wang, M.D. Radiation Oncology · Chapel Hill, NC
- Martin E. Gutierrez, MD Medical Oncology · Hackensack, NJ
- Liza C. Villaruz, M.D. Internal Medicine · Pittsburgh, PA
- Steven F. Powell, M.D. Hematology & Oncology · Sioux Falls, SD
- David C. Starks, MD Gynecologic Oncology · Sioux Falls, SD
- Jenny J. Li, M.D. Medical Oncology · Houston, TX
- Caroline Nebhan Hematology & Oncology · Murray, UT
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
- Rafael Santana Davila, MD Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Massachusetts General Hospital, MA $242,019
- Florida Cancer Specialist (scri) - Fort Myers $176,070
- Dana Farber Mass General Brigham Cancer Care Inc $154,418
- University of Washington Medical Ctr, WA $108,077
- Intermountain Health Utah Valley Hospital, UT $98,776
- Avera Mckennan Hospital & University Health Center, SD $70,049
- Banner Casa Grande Medical Center, AZ $51,558
- UPMC Cancer Centers $51,327
- Sanford Research $37,948
- Ut MD Anderson Cancer Center $27,023
- The University of Texas Southwestern Med $24,238
- Karmanos Cancer Center, MI $12,552
- Next Virginia, LLC $9,554
- Hackensack University Medical Center, NJ $7,889
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.